A phase II trial found tislelizumab plus radiotherapy and chemotherapy improved tumour regression in locally advanced rectal cancer.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.